How Does BioTelemetry’s (NASDAQ:BEAT) P/E Compare To Its Industry, After The Share Price Drop?

To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 41% in the last month. That drop has capped off a tough year for shareholders, with the share price down 51% in that time.

Assuming nothing else has changed, a lower share price makes a stock more attractive to potential buyers. While the market sentiment towards a stock is very changeable, in the long run, the share price will tend to move in the same direction as earnings per share. So, on certain occasions, long term focussed investors try to take advantage of pessimistic expectations to buy shares at a better price. Perhaps the simplest way to get a read on investors’ expectations of a business is to look at its Price to Earnings Ratio (PE Ratio). A high P/E implies that investors have high expectations of what a company can achieve compared to a company with a low P/E ratio.

View our latest analysis for BioTelemetry

How Does BioTelemetry’s P/E Ratio Compare To Its Peers?

We can tell from its P/E ratio of 35.82 that there is some investor optimism about BioTelemetry. As you can see below, BioTelemetry has a higher P/E than the average company (18.6) in the healthcare industry.

NasdaqGS:BEAT Price Estimation Relative to Market, March 20th 2020
NasdaqGS:BEAT Price Estimation Relative to Market, March 20th 2020

BioTelemetry’s P/E tells us that market participants think the company will perform better than its industry peers, going forward. Shareholders are clearly optimistic, but the future is always uncertain. So investors should always consider the P/E ratio alongside other factors, such as whether company directors have been buying shares.

How Growth Rates Impact P/E Ratios

When earnings fall, the ‘E’ decreases, over time. That means even if the current P/E is low, it will increase over time if the share price stays flat. A higher P/E should indicate the stock is expensive relative to others — and that may encourage shareholders to sell.

BioTelemetry saw earnings per share decrease by 33% last year. And it has shrunk its earnings per share by 23% per year over the last three years. This could justify a low P/E.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

It’s important to note that the P/E ratio considers the market capitalization, not the enterprise value. That means it doesn’t take debt or cash into account. The exact same company would hypothetically deserve a higher P/E ratio if it had a strong balance sheet, than if it had a weak one with lots of debt, because a cashed up company can spend on growth.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

Is Debt Impacting BioTelemetry’s P/E?

BioTelemetry has net debt worth 12% of its market capitalization. It would probably deserve a higher P/E ratio if it was net cash, since it would have more options for growth.

The Bottom Line On BioTelemetry’s P/E Ratio

BioTelemetry has a P/E of 35.8. That’s higher than the average in its market, which is 12.2. With modest debt but no EPS growth in the last year, it’s fair to say the P/E implies some optimism about future earnings, from the market. Given BioTelemetry’s P/E ratio has declined from 61.2 to 35.8 in the last month, we know for sure that the market is significantly less confident about the business today, than it was back then. For those who don’t like to trade against momentum, that could be a warning sign, but a contrarian investor might want to take a closer look.

Investors should be looking to buy stocks that the market is wrong about. People often underestimate remarkable growth — so investors can make money when fast growth is not fully appreciated. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course you might be able to find a better stock than BioTelemetry. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.